Biopharma 4.0: Digitalized, Intensified, and Continuous Bioprocessing

The growing demand for new therapies, the persistent pressure to reduce costs, and the success of novel modalities, are driving a change in the biopharmaceutical industry.

Whether it’s called the Digitalization of Biotech, Bioprocessing 4.0, or the Biomanufacturing Facility of the Future, there are many objectives to balance. To stay competitive, emerging and established biotechs, as well as C(D)MOs, need to increase speed, efficiency, agility, and scalability, without compromising quality or compliance. Layered upon these requirements is the necessity to deliver greater value and align with corporate sustainability goals - all within a highly regulated environment.

Digital Biomanufacturing: Evolution towards the facility of the future

Your digital transformation can accelerate access to biopharmaceuticals for patients worldwide. To position you for success and help you achieve your ambitious biomanufacturing goals across different modalities and production scales, we offer a convergent end-to-end portfolio of advanced, closed processing-ready upstream and downstream technologies. Coupled with process analytical technologies (PAT), our data analytics, automation, and control software advance unit, plant, and enterprise level digital maturity.

No matter your path – developing an intensified or continuous bioprocess or an autonomous facility of the future – the BioContinuum™ Platform provides the building blocks and expertise to help you gain new levels of performance and productivity.

BioContinuum™ Platform: Your enabler of the biomanufacturing facility of the future!